Innovating Works

ANAXOMICS BIOTECH

Activa
Showing 1 to 20 of 23 results
halt-RONIN: Discovering chronic inflammation biomarkers that define key stages in the Healthy to NASH non alcoh... ANAXOMICS BIOTECH participó en un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a si...
2022-11-22 - 2026-11-30 | Financiado
PROTrEIN: Computational Proteomics Training European Innovative Network ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2020 PROTrEIN is a Training Network composed of 12 beneficiaries, and 8 partner organizations, from the academic and non-academic sectors with th...
2020-08-18 - 2024-12-31 | Financiado
DISCOvERIE: Development dIagnostic and prevention of gender related Somatic and mental COmorbitiEs in iRritable... ANAXOMICS BIOTECH participó en un H2020: H2020-SC1-BHC-2018-2020 Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable b...
2019-12-13 - 2024-12-31 | Financiado
SMA-TB: A novel Stratified Medicine Algorithm to predict treatment responses to host directed therapy in TB... ANAXOMICS BIOTECH participó en un H2020: H2020-SC1-BHC-2018-2020 Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Healt...
2019-12-06 - 2024-12-31 | Financiado
RECOGNISED: Retinal and cognitive dysfunction in type 2 diabetes unraveling the common pathways and identificat... ANAXOMICS BIOTECH participó en un H2020: H2020-SC1-BHC-2018-2020 In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be con...
2019-11-21 - 2024-12-31 | Financiado
SECRET: Exploitation of the SECRETory pathway for cancer therapy to address European research ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2019 Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of t...
2019-08-09 - 2023-09-30 | Financiado
proEVLifeCycle: The life cycle of extracellular vesicles in prostate cancer from biogenesis and homing to function... ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2019 The prostate cancer Extracellular Vesicle LifeCycle (proEVLifeCycle) network is an innovative, multidisciplinary training program focused on...
2019-08-09 - 2023-09-30 | Financiado
Capsulight: The first ingestible capsule for eradicating Helicobacter pylori infection through photodynamic ther... ANAXOMICS BIOTECH participó en un H2020: H2020-EIC-SMEInst-2018-2020 Helicobacter pylori (H. pylori) is a bacterium of the stomach which affects on average 50% of the world population, reaching up to 70% in so...
2019-01-23 - 2019-07-31 | Financiado
LEGACy: CeLac and European consortium for a personalized medicine approach to Gastric Cancer ANAXOMICS BIOTECH participó en un H2020: H2020-SC1-BHC-2018-2020 Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The hi...
2018-12-08 - 2023-06-30 | Financiado
HELICAL: HEalth data LInkage for ClinicAL benefit ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2018 European researchers have made leading contributions to the large genomic, transcriptomic and clinical datasets from patients with chronic d...
2018-08-31 - 2023-06-30 | Financiado
DRIVE: Driving next generation autophagy researchers towards translation ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2017 The manipulation of autophagy has an enormous therapeutic potential to revolutionize the way we currently treat cancers, neurodegenerative d...
2017-08-31 - 2022-04-30 | Financiado
COSMIC: COmbatting disorders of adaptive immunity with Systems MedICine ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2017 Background: EU countries face large health challenges to combat chronic diseases. Recently, systems medicine has emerged as a promising disc...
2017-08-30 - 2022-09-30 | Financiado
LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS ANAXOMICS BIOTECH participó en un H2020: H2020-SC1-2016-2017 Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact...
2016-12-09 - 2023-02-28 | Financiado
TREATMENT: Training European Network Metabolic Dysfunctions associated with Pharmacological Treatment of Schiz... ANAXOMICS BIOTECH participó en un H2020: H2020-MSCA-ITN-2016 TREATMENT is a Marie Sklodowska Curie Innovative Training Network proposal directly addressing the need for high-level training and career p...
2016-08-31 - 2021-06-30 | Financiado
SYSMALVAC: Identifying correlates of protection to accelerate vaccine trials systems evaluation of two models... Vaccine development is an empirical process (trial and error) and involves a long, expensive clinical development pipeline to license an eff...
Financiado
INDOX: Optimized oxidoreductases for medium and large scale industrial biotransformations ANAXOMICS BIOTECH participó en un FP7: The INDOX proposal on industrial oxidoreductases aims to provide relevant industrial case stories to demonstrate the efficacy of optimized b...
Financiado
RAPID: Rheumatoid Arthritis and Periodontal Inflammatory Disease RAPID ANAXOMICS BIOTECH participó en un FP7: The most prevalent chronic inflammatory diseases of humans are complex disorders of multifactorial aetiology influenced by genes, the enviro...
Financiado
VISION: Prolonged inhibition of semaphorine3a pathway via a bio degradable implant towards a better therapy... ANAXOMICS BIOTECH participó en un FP7: The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative. Acute optic nerve injury, ischemic...
Financiado
GUMS AND JOINTS: Protein citrullination as a link between periodontal diseases and rheumatoid arthritis RA and targ... ANAXOMICS BIOTECH participó en un FP7: Autoimmunity in rheumatoid arthritis (RA) is characterised by an antibody response to citrullinated proteins. Periodontitis (PD) is largely...
Financiado
TRIGGER: King of hearts joints and lungs periodontal pathogens as etiologic factor in RA CVD and COPD and... ANAXOMICS BIOTECH participó en un FP7: Extensive clinical and epidemiological data clearly shows that chronic periodontal disease (PD), the most prevalent infectious inflammatory...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.